Forward-looking Statements

This presentation contains forward-looking statements, within the meaning of federal securities laws, related to future events and future financial performance which include statements about our expectations, beliefs, plans, objectives, intentions, goals, strategies, assumptions and other statements that are not historical facts. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions, which could cause actual results to differ materially from expected results, performance or achievements expressed or implied by statements made herein. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including, but not limited to; uncertainties relating to the time required to build inventory and establish commercial operations in Europe, CE Marking for the Generation Two CHEMOSAT system, future initial training and marketing agreements with centers in the EEA, patient outcome from CHEMOSAT treatments, adoption, use and resulting sales, if any, for the CHEMOSAT system in the EEA, our ability to successfully commercialize the CHEMOSAT system and the potential of the system as a treatment for patients with cancer in the liver, availability of melphalan in the EEA, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company’s NDA by the FDA, approval of the Company’s NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications or the same indication in other foreign markets, actions by the FDA or other foreign regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, our ability to secure reimbursement for the chemosaturation system, progress of our research and development programs; timing and results of future clinical trials, uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities, overall economic conditions and other factors described in our filings with the Securities and Exchange Commission including the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K and our Reports on Form 10-Q and Form 8-K.
Delcath Systems – Company Highlights

• A specialty pharmaceutical and medical device company focused on oncology

• CHEMOSAT is a repeatable, percutaneous procedure that is uniquely positioned to treat the entire liver as standalone or potentially complementary therapy

• Multi-billion dollar annual global revenue market opportunity

• Statistically significant clinical trial results demonstrating improvement in disease control in the liver

• CHEMOSAT CE Mark approved for broad use in liver cancers
  o Commenced initial treatment procedures in Europe

• Seeking regulatory approval in multiple other markets including the U.S.
  o Expected NDA submission to the FDA by the end of Q2 2012

• IP and orphan drug designations create competitive barriers

• Seasoned management team with average experience of ~25 years and track records of building shareholder value

Concentrating the Power of Chemotherapy for Disease Control in the Liver
What is CHEMOSAT

• CHEMOSAT is a drug delivery system designed for regional chemotherapy for cancers in the liver

1. Utilize three catheters to **ISOLATE** the circulatory system of the liver

2. **SATURATE** the liver with a high dose of anti-cancer agent (melphalan) to destroy the tumors (both visible and invisible)

3. **FILTRATE** the chemo-drug laden blood through Delcath’s proprietary filtration system prior to returning it to the patient

- Control systemic exposure and related side effects
- The procedure is minimally invasive and repeatable

Concentrating the Power of Chemotherapy for Disease Control in the Liver
Initial Focus on Cancers in the Liver

• Few effective therapies are available for cancers in the liver
  - Large patient population diagnosed annually with primary or metastatic liver cancer
  - The liver is often the life limiting organ for cancer patients and one of the leading causes of cancer death
  - Prognosis after liver involvement is poor

• CHEMOSAT is uniquely positioned to treat the entire liver as standalone or complementary therapy

• Multi-billion dollar annual global revenue market opportunity
## Existing Liver Cancer Treatments Have Limitations

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systemic</strong></td>
<td>– Non-invasive</td>
<td>– Systemic toxicities</td>
</tr>
<tr>
<td></td>
<td>– Repeatable</td>
<td>– Limited efficacy in liver</td>
</tr>
<tr>
<td><strong>Regional</strong> (e.g., Isolated Hepatic Perfusion)</td>
<td>– Therapeutic effect</td>
<td>– Invasive/limited repeatability</td>
</tr>
<tr>
<td></td>
<td>– Targeted</td>
<td>– Multiple treatments are required, not possible</td>
</tr>
<tr>
<td><strong>Focal</strong> (e.g. surgery, radioembolization or SIRT, chemoembolization or TACE, radio frequency ablation or RFA)</td>
<td>– Partial removal or treatment of tumors</td>
<td>– Only 10% to 20% resectable</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Invasive and/or limited repeatability</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Treatment is limited by tumor size, number of lesions and location</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– “See a tumor, treat a tumor”</td>
</tr>
</tbody>
</table>

---

Unmet Medical Need Exists for More Effective Liver Cancer Treatments
Isolated Hepatic Perfusion: Proof of Concept, but High Morbidity and Non-Repeatable
The Delcath CHEMOSAT System

1) **ISOLATE** the circulatory system of the liver using three catheters

2) **SATURATE** the liver with a high dose of anti-cancer agent (melphalan) to destroy the tumors (both visible and invisible)

3) **FILTRATE** the chemo-drug laden blood through Delcath’s proprietary filtration system prior to returning it to the patient

- No more open surgery
- Minimally invasive, repeatable
- Treats entire liver (macro and micro)
- Allows for over 100x effective dose escalation of drug agents at tumor site
- Improved disease control in the liver
- Minimizes systemic toxicities
- Complements systemic therapy

Minimally Invasive, Repeatable Liver Procedure That Could Complement Systemic Therapy

Note: Image not to scale.
## Melphalan Dosing & Background

<table>
<thead>
<tr>
<th>Type</th>
<th>Dosing (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple Myeloma (label)</td>
<td>0.25</td>
</tr>
<tr>
<td>Chemoembolization</td>
<td>0.62</td>
</tr>
<tr>
<td>Surgical Isolated Hepatic Perfusion (IHP)</td>
<td>1.50</td>
</tr>
<tr>
<td>Myeloablation</td>
<td>2.50-3.50</td>
</tr>
<tr>
<td><strong>Chemosaturation (PHP)</strong></td>
<td><strong>3.00</strong></td>
</tr>
</tbody>
</table>

- Well understood, dose dependant, tumor preferential, alkylating cytotoxic agent that demonstrates little to no hepatic toxicity
- Manageable systemic toxicities associated with Neutropenia and Thrombocytopenia
- Drug dosing **12x higher** than FDA-approved dose via systemic IV chemotherapy
- Dose delivered to tumor is over **100x higher** than that of systemic IV chemotherapy

---

An Established Drug for Liver Cancer Therapy
CHEMOSAT - Potential Multi-Billion Dollar Market

Estimated $7 Billion Annual Global Revenue Opportunity, Near Term Primarily in Europe

Sources: LEK Consulting, GLOBOCAN, Company estimates.
*TPM for initial U.S. labeled indication only.
EU: Initial target countries of Germany, UK, Italy, France, Spain, Netherlands, Ireland.
APAC: Initial target countries of China, Japan, S. Korea, Taiwan, Australia.
Assumes 2.5 treatments per patient.
Assumes EU ASP of $15K; US ASP of $25K; APAC ASP of $5K.
Current Patient Referral Path

Patient

Identification of liver involvement with no improvement from systemic therapy

Primary Care

Diagnosis of Cancer

Medical Science Liaison

Medical Oncologist

Offers systemic therapy

Surgical Oncologist

Offers resection or other focal therapy

When liver disease is controlled, patients return to the Medical Oncologist for additional systemic therapy

Medical Science Liaison

Transferred for chemosaturation

Delcath Sales & Marketing

Interventional Radiologist

Offers chemosaturation procedure
European Commercialization Strategy

Overview:

- Broad device indication for “percutaneous intra-arterial delivery of a chemotherapeutic agent (melphalan hydrochloride) to the liver”
- Melphalan for injection approved in 14 countries and commercially available
- Hospitals procure melphalan separately from existing sources
- Initial focus on top 6 countries (DE, UK, NL, FR, IT, SP) and Ireland
  - Direct sales in DE, UK, and NL
  - Indirect sales via distributors in FR, IT, and SP
- Push and Pull strategy
- EU headquarters in Galway, Ireland

Currently at Initial Training and Marketing Phase
CHEMOSAT Training and Marketing Commenced in Europe

- Entered training and marketing agreements with leading cancer centers in Europe
  - Institute of European Oncology (IEO), Milan, Italy
  - Johann Wolfgang Goethe (JWG) University Hospital, Frankfurt, Germany
  - University Medical Center Schleswig-Holstein, Kiel Campus, Germany
- Training completed and first patients treated at IEO and JWG University Hospital, Frankfurt, Germany
  - Cutaneous melanoma, ocular melanoma, gastric cancer, and breast cancer liver metastases
- Agreements with additional leading cancer centers expected in France, UK, Spain, the Netherlands, and Ireland in 1H 2012
Team at Institute of European Oncology Performs 1st EU CHEMOSAT Procedure

January 31, 2012
European Reimbursement Considerations

- No centralized pan-European medical device reimbursement body – regional and national systems
- Devices typically reimbursed under Diagnosis Related Groups (DRG) as part of a procedure
- Working with reimbursement specialists to develop a plan in each of our key markets
- Immediate reimbursement plans:
  - Utilize existing codes where permitted until permanent reimbursement established (e.g. Italy)
  - Apply for funding under existing New Technology Payment programs (e.g. NUB in Germany and HAS in France)
  - Other oncology therapies currently reimbursed, despite lacking randomized data

Reimbursement Mechanisms in Place to Support Commercial Launch
**Positive Phase III Results**

- **Primary endpoint exceeded, p value = 0.0001, hazard ratio of .35**
  - Treatment arm shows 5x median hepatic progression free (hPFS) survival compared to control arm
  - CS/PHP median hPFS of 8.0 months compared to 1.6 months for BAC
  - 86% overall clinical benefit (CR + PR + SD)

- **Secondary endpoints support results**
  - OS Secondary endpoint – No difference in Kaplan-Meier curves due to cross over treatment response (9.8 months compared to 9.9 months)
  - CS/PHP median overall PFS of 6.7 months vs. 1.6 months for BAC

- **OS exploratory cohort analysis favorable**
  - Median survival of 9.8 months for treatment arm compared to 4.1 months non-crossover BAC patients
  - Median survival of 11.4 months for all patients treated with melphalan, including crossover
  - 9 CS/PHP-treated patients and 3 BAC-treated patients still alive as of 12/2011

- **Safety profile – expected and consistent with currently approved labeling for melphalan**
  - 30-day deaths on PHP: 3/44 patients (6.8%)
    - 1 Neutropenic Sepsis (2.3%); 1 Hepatic Failure 2.5% (95% tumor burden); 1 gastric perforation
  - 30-day deaths on BAC: 3/49 patients (6.1%)

* Updated Investigator results presented at 2011 ECCO/ESMO Annual Meeting.

**Trial Outcomes Favorable and Consistent with Special Protocol Assessment**
# Phase II NCI Trial – Metastatic Neuroendocrine Cohort

## Phase II mNET Tumor Cohort (n=24)*

<table>
<thead>
<tr>
<th></th>
<th>Number (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Tumor Histology</strong></td>
<td></td>
</tr>
<tr>
<td>Carcinoid</td>
<td>4</td>
</tr>
<tr>
<td>Pancreatic Islet Cell</td>
<td>20</td>
</tr>
<tr>
<td><strong>Response</strong></td>
<td></td>
</tr>
<tr>
<td>Not Evaluable (Toxicity, Incomplete Treatment, Orthotopic Liver Transplantation)</td>
<td>4</td>
</tr>
<tr>
<td>Progressive Disease</td>
<td>2</td>
</tr>
<tr>
<td>Minor Response / Stable Disease</td>
<td>4</td>
</tr>
<tr>
<td><strong>Partial Response (30.0% - 99.0% Tumor Reduction)</strong></td>
<td>13</td>
</tr>
<tr>
<td><strong>Complete Response (No Evidence of Disease)</strong></td>
<td>1</td>
</tr>
<tr>
<td><strong>Objective Tumor Response</strong></td>
<td>14</td>
</tr>
</tbody>
</table>
| **Objective Tumor Response Rate** | 70%

<table>
<thead>
<tr>
<th></th>
<th>Duration (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median Hepatic PFS</td>
<td>15.5</td>
</tr>
<tr>
<td>Overall Survival After CS</td>
<td>30.4</td>
</tr>
</tbody>
</table>

*Presentation at ECCO/ESMO 2011 annual meeting.

Compelling Clinical Data in Attractive mNET Market
Phase II NCI Trial – HCC Cohort

• Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, with approximately 749,000* new cases diagnosed worldwide annually

• Nine patients with tumors of hepatobiliary origin: five HCC patients and four cholangiocarcinoma patients

• Both groups received CHEMOSAT procedures and had positive efficacy signals

• The responses were especially encouraging in the HCC group and consisted of confirmed partial response or durable stable disease

• Safety profile – expected and consistent with pivotal US Phase III melanoma trial

• Intend to invest in new HCC trials with CHEMOSAT

*Source: GLOBOCAN

Encouraging Initial Positive Signal for Primary Liver Cancer
Substantial clinical evidence of benefit of using melphalan to treat mCRC via isolated hepatic perfusion (IHP) procedure
  - Over 800 patients treated in 15 studies since 1998
  - Patients treated only once
  - Median response rate of 47% (range 29%-76%)1

Delcath Phase II NCI CHEMOSAT Trial – mCRC Cohort
  - Challenges enrolling at NCI
  - 16 patients treated since 2004
  - Inconclusive efficacy due to advanced disease status (generally 5th or 6th line)
  - Safety profile – expected and consistent with pivotal FDA Phase III melanoma trial

Intend to invest in new mCRC trials with CHEMOSAT Melphalan

U.S. FDA Regulatory Status

• Pre-NDA submission meeting with FDA conducted in January 2012
  o Satisfied with FDA response
  o Addressed RTF related issues
    ▪ Manufacturing plant inspection timing
    ▪ Product and sterilization validation
    ▪ Additional statistical analysis clarification
    ▪ Additional safety data

• Continued progress in finalizing data entry and monitoring
  o Completed data migration to new FDA compliant database
  o Created new Case Report Form (CRF)

• Plan to file NDA submission by the end of Q2 2012

Progress on Track to Submit NDA
U.S. Commercialization Strategy

• Initial focus on leading cancer centers and referring community hospitals
• Educate Medical Oncologists via Medical Science Liaison (MSL)
• Direct strategy to sell to Interventional Radiologists and Surgeons: 12 sales territories ultimately expanding to as many as 60 territories as revenues ramp
• 5 Clinical Specialists initially to support site initiation and training
• Utilize top centers from Phase III trial as Centers of Excellence for training and support
• Intend to seek chemosaturation specific codes based upon value proposition relative to other cancer therapies

Direct Sales Channels Supplemented with Contract MSLs
International Strategy beyond EU and US

• Leverage CE Mark to obtain reciprocal regulatory approvals for CHEMOSAT System in other international markets

• International regulatory submissions status:
  
  ➢ **Application submitted**
    ▪ Australia - 2012 (approved)
    ▪ Hong Kong - 2012
    ▪ S. Korea - 2013
    ▪ Singapore - 2013
  
  ➢ **Intend to submit applications**
    ▪ Israel
    ▪ Canada
    ▪ Mexico/Argentina/Brazil
    ▪ Russia
    ▪ India
    ▪ Japan
    ▪ China and Taiwan

• Utilize 3rd party melphalan and doxorubixin available to physicians

Combination of Strategic Partnerships and Specialty Distributors
### Product Development Pipeline

<table>
<thead>
<tr>
<th>Region</th>
<th>Initial Opportunity</th>
<th>Near Term (&lt; 5 years)</th>
<th>Intermediate Term (&gt; 5 years)</th>
</tr>
</thead>
</table>
| **EU** | • All liver cancers – melphalan  
• Class III medical device  
• 3rd party melphalan  
• Gen 2 melphalan CE Mark | • CHEMOSAT Doxorubicin CE Mark  
• mCRC and HCC clinical trials | • CHEMOSAT for additional drugs  
• CHEMOSAT for other organs (lung and brain) |
| **ASIA** | • CHEMOSAT Melphalan in Australia and Hong Kong  
• 3rd party melphalan | • CHEMOSAT Melphalan in South Korea, Japan  
• CHEMOSAT Doxorubicin in China and Taiwan  
• 3rd party doxorubicin | • CHEMOSAT for additional drugs  
• CHEMOSAT for other organs (lung and brain) |
| **US** | • Melanoma liver mets  
• Proprietary drug-melphalan & CHEMOSAT | • mCRC and HCC indications | • CHEMOSAT for additional drugs  
• CHEMOSAT for other organs (lung and brain) |

**Development Aligned to Address Significant Market Opportunity**
Generation Two CHEMOSAT Melphalan

• Status:
  o Consistent first pass removal efficiency of 98% or better in both *in vitro* and pre-clinical GLP animal studies
  o New trade secret manufacturing process for filter medium
  o Filed for CE marking for Gen Two
  o Anticipate approval in 1Q 2012

• Expected Benefits:
  o Reduced systemic toxicity
  o Concomitant therapy (complements systemic therapies)
  o Increased utility in a wider range of patients
CHEMOSAT Doxorubicin Development

- Multiple published Phase I/II studies from MD Anderson Cancer Center and Yale with percutaneous hepatic perfusion (PHP) and Kobe University using doxorubicin show promising response rates for HCC*

- Status:
  - First pass removal efficiency 95% in initial in vitro studies
  - Utilize new trade secret manufacturing process
  - Intend to file and seek CE Mark approval in 2H 2012
  - Plan to use CHEMOSAT Doxorubicin in Asia Phase III 2L HCC trials

- Expected Benefits:
  - Multiple treatments
  - Reduced systemic toxicity for improved safety profile
  - Concomitant therapy (complements systemic therapies)

*See Appendix III for list of studies

Addressing the Large HCC Market Opportunity in China
Clinical Development Program

• Goal:
  o Expand indications for HCC and mCRC with US registration trials
  o Generate robust clinical data to support commercialization

• Planned Clinical Trials: (2012 – 2013 Start)
  o HCC
    ▪ Global Phase 2 randomized 1L CHEMOSAT Melphalan vs. Sorafenib
    ▪ US registration – Global Phase 3 Randomized 2L CHEMOSAT Melphalan vs. BSC for Sorafenib Failure
    ▪ Asia Phase 3 Randomized 2L CHEMOSAT Doxorubicin vs. BSC for Sorafenib Failure
  o mCRC
    ▪ Global Phase 2 Signal Seeking/Safety 2L CHEMOSAT Melphalan
    ▪ US Registration – Global Phase 3 Randomized 2L CHEMOSAT Melphalan vs. Approved Alternatives

• US Expanded Access Program (EAP) for metastatic melanoma

Establish CHEMOSAT as the Standard of Care (SOC) for Disease Control in the Liver
Intellectual Property

• Patent Protection
  o 7 issued U.S. patents, 10 foreign patents issued and 4 pending
  o Primary device patent set to expire August 2016
  o Up to 5 years of patent extension post FDA approval

• Trade Secret Protection
  o Developed improved filter media via new manufacturing processes

• FDA Protection
  o Orphan Drug Designation granted for melphalan in the treatment of ocular melanoma, cutaneous melanoma and metastatic neuroendocrine tumors, as well as for doxorubicin in the treatment of HCC
    ▪ Provides 7 years of marketing exclusivity post FDA approval
  o Additional Orphan Drug applications to be filed for other drugs and indications, including melphalan for HCC and CRC

Multiple Levels of Protection
<table>
<thead>
<tr>
<th>Executive</th>
<th>Title</th>
<th>Prior Affiliation(s)</th>
<th>Years of Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eamonn Hobbs</td>
<td>President and CEO</td>
<td>AngioDynamics, E-Z-EM</td>
<td>31</td>
</tr>
<tr>
<td>Graham Miao, Ph.D</td>
<td>EVP &amp; CFO</td>
<td>D&amp;B, Pagoda Pharma, Schering-Plough, Pharmacia, JP Morgan</td>
<td>22</td>
</tr>
<tr>
<td>Krishna Kandarpa, M.D., Ph.D.</td>
<td>CMO and EVP, R&amp;D</td>
<td>Harvard, MIT(HST), Cornell, UMass</td>
<td>32</td>
</tr>
<tr>
<td>Agustin Gago</td>
<td>EVP, Global Sales &amp; Marketing</td>
<td>AngioDynamics, E-Z-EM</td>
<td>30</td>
</tr>
<tr>
<td>Peter Graham, J.D.</td>
<td>EVP, General Counsel &amp; Global Human Resources</td>
<td>Bracco, E-Z-EM</td>
<td>17</td>
</tr>
<tr>
<td>David McDonald</td>
<td>EVP Business Development</td>
<td>AngioDynamics, RBC Capital Markets</td>
<td>29</td>
</tr>
<tr>
<td>John Purpura</td>
<td>EVP, Regulatory Affairs &amp; Quality Assurance</td>
<td>E-Z-EM, Sanofi-Aventis</td>
<td>28</td>
</tr>
<tr>
<td>Harold Mapes</td>
<td>EVP, Global Operations</td>
<td>AngioDynamics, Mallinkrodt</td>
<td>26</td>
</tr>
<tr>
<td>Bill Appling</td>
<td>SVP Medical Device R&amp;D</td>
<td>AngioDynamics</td>
<td>26</td>
</tr>
<tr>
<td>J. Chris Houchins</td>
<td>SVP, Clinical and Medical Affairs</td>
<td>Arno, Schering-Plough, Pfizer, Pharmacia, GD Searle</td>
<td>21</td>
</tr>
<tr>
<td>Dan Johnston, Ph.D.</td>
<td>VP, Pharmaceutical R&amp;D</td>
<td>Pfizer, Wyeth</td>
<td>11</td>
</tr>
</tbody>
</table>
# Financial Update

<table>
<thead>
<tr>
<th><strong>Cash &amp; Cash Equivalents:</strong></th>
<th>$30.8 million at December 31, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Financing Program</strong></td>
<td>$39.75 million At-The-Market (ATM) program</td>
</tr>
<tr>
<td><strong>Cash Spend:</strong></td>
<td>$40.1 million full year 2011</td>
</tr>
<tr>
<td><strong>Debt:</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Shares Outstanding:</strong></td>
<td>48 million (~55 million fully diluted(^1))</td>
</tr>
<tr>
<td><strong>Market Cap (as of 2/28/12):</strong></td>
<td>$220 million</td>
</tr>
<tr>
<td><strong>Avg. Daily Volume (3 mo.):</strong></td>
<td>624,000</td>
</tr>
</tbody>
</table>

---

1) As of December 31, 2011 fully diluted includes an additional 4.1 million options at $5.09, 2.5 million warrants at $3.51, and 193,532 unvested restricted shares.
2012 Milestones

- First patients have been treated with CHEMOSAT Melphalan in Europe
- Executed contract for MSL services in EU – 1Q 2012 (Quintiles was selected to support EU launch of CHEMOSAT)
- Secure agreements with 6-8 leading cancer centers in EU (3 in place currently) – 1H
- Obtain CE Mark for Gen 2 CHEMOSAT Melphalan – 1Q 2012
- US NDA submission in 2Q 2012 and acceptance in 3Q 2012
- Submission for publications of Phase III data and mNET arm of Phase II data – 2H 2012
- First patients enrolled in mCRC and HCC CHEMOSAT Melphalan studies, EAP – 2H 2012
- Submit and seek approval of CE Mark for CHEMOSAT Doxorubicin – 2H 2012
- Potential Asia strategic partnership – dedicated BD with China a top priority
Appendices
Appendix I

CHEMOSAT Market Opportunity
by Disease and Target Counties
Market Opportunity by Disease (patients)

- Europe – Largest near-term opportunity
- CRC – Largest opportunity worldwide
- Melanoma – Largest opportunity is in US
- China - Largest opportunity for HCC

**Market Opportunity defined as Total Potential Market (TPM) for CHEMOSAT®**

1. Primary cancer incidence
2. Adjusted for predominant disease in the liver (primary or metastatic cancer)
3. Adjusted for addressable patients via Delcath CHEMOSAT®
### Europe Market by Disease – Device Only

<table>
<thead>
<tr>
<th>Disease</th>
<th>Germany (Direct)</th>
<th>UK (Direct)</th>
<th>France (Indirect)</th>
<th>Italy (Indirect)</th>
<th>Spain (Indirect)</th>
<th>Netherlands (Direct)</th>
<th>Ireland (Direct)</th>
<th>Total Potential (patients)</th>
<th>Potential Market ($ MM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular Melanoma</td>
<td>404</td>
<td>297</td>
<td>295</td>
<td>285</td>
<td>197</td>
<td>79</td>
<td>19</td>
<td>1,576</td>
<td>$ 62</td>
</tr>
<tr>
<td>Cutaneous Melanoma</td>
<td>1,625</td>
<td>994</td>
<td>753</td>
<td>801</td>
<td>360</td>
<td>379</td>
<td>73</td>
<td>4,987</td>
<td>$ 206</td>
</tr>
<tr>
<td>CRC</td>
<td>9,902</td>
<td>5,300</td>
<td>5,475</td>
<td>7,281</td>
<td>4,016</td>
<td>1,644</td>
<td>335</td>
<td>33,953</td>
<td>$1,339</td>
</tr>
<tr>
<td>HCC (Primary)</td>
<td>1,637</td>
<td>720</td>
<td>1,514</td>
<td>2,597</td>
<td>1,087</td>
<td>82</td>
<td>35</td>
<td>7,671</td>
<td>$277</td>
</tr>
<tr>
<td>NET</td>
<td>1,783</td>
<td>1,336</td>
<td>1,353</td>
<td>1,299</td>
<td>974</td>
<td>360</td>
<td>98</td>
<td>7,202</td>
<td>$281</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>15,351</strong></td>
<td><strong>8,647</strong></td>
<td><strong>9,389</strong></td>
<td><strong>12,263</strong></td>
<td><strong>6,634</strong></td>
<td><strong>2,545</strong></td>
<td><strong>560</strong></td>
<td><strong>55,389</strong></td>
<td><strong>$2,166</strong></td>
</tr>
</tbody>
</table>

Sources: LEK Consulting, GLOBOCAN, Company estimates.
1) Assumes 2.5 treatments per patient.
2) Assumes ASP of ~$15K USD.
3) Assumes mix of direct sales and distributors.

Europe Presents Significant Potential Market Opportunity
### US Market by Disease – Device and Drug Combination

<table>
<thead>
<tr>
<th>Liver Metastasis</th>
<th>Potential Market # Patients</th>
<th>Potential Market # Procedures</th>
<th>Potential Market ($MM)(^{1,2})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular Melanoma</td>
<td>1,685</td>
<td>4,213</td>
<td>$105</td>
</tr>
<tr>
<td>Cutaneous Melanoma</td>
<td>7,023</td>
<td>17,557</td>
<td>$439</td>
</tr>
<tr>
<td><strong>TOTAL MELANOMA</strong> (Initial Expected Label)</td>
<td><strong>8,708</strong></td>
<td><strong>21,770</strong></td>
<td><strong>$544</strong></td>
</tr>
<tr>
<td>CRC</td>
<td>19,861</td>
<td>49,653</td>
<td>$1,241</td>
</tr>
<tr>
<td>HCC (Primary)</td>
<td>5,586</td>
<td>13,964</td>
<td>$349</td>
</tr>
<tr>
<td>NET</td>
<td>8,212</td>
<td>20,530</td>
<td>$513</td>
</tr>
<tr>
<td><strong>OTHER TOTAL</strong> (Potential Label Expansion)</td>
<td><strong>33,659</strong></td>
<td><strong>84,147</strong></td>
<td><strong>$2,104</strong></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>42,367</strong></td>
<td><strong>105,917</strong></td>
<td><strong>$2,648</strong></td>
</tr>
</tbody>
</table>

Sources: LEK Consulting, GLOBOCAN, Company estimates.
1) Assume 2.5 treatments per patient.
2) Estimated ASP of $25K.
# APAC Market by Disease

<table>
<thead>
<tr>
<th></th>
<th>China (Device)</th>
<th>S. Korea (Device)</th>
<th>Japan (Device)</th>
<th>Taiwan (Device)</th>
<th>Australia (Device)</th>
<th>Total Potential (patients)</th>
<th>Potential Market ($MM)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Potential Market</strong> #Patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCC (Primary)</td>
<td>85,780</td>
<td>3,258</td>
<td>8,296</td>
<td>2,152</td>
<td>263</td>
<td>99,749</td>
<td>$ 1,156</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRC</td>
<td>31,127</td>
<td>3,245</td>
<td>14,298</td>
<td>1,441</td>
<td>2,031</td>
<td>52,143</td>
<td>$ 642</td>
</tr>
<tr>
<td>NET</td>
<td>29,197</td>
<td>1,048</td>
<td>2,759</td>
<td>500</td>
<td>462</td>
<td>33,966</td>
<td>$ 393</td>
</tr>
<tr>
<td>Ocular Melanoma</td>
<td>1,765</td>
<td>66</td>
<td>175</td>
<td>31</td>
<td>96</td>
<td>2,134</td>
<td>$ 25</td>
</tr>
<tr>
<td>Cutaneous Melanoma</td>
<td>382</td>
<td>43</td>
<td>136</td>
<td>246</td>
<td>1,144</td>
<td>1,951</td>
<td>$ 23</td>
</tr>
<tr>
<td><strong>OTHER TOTAL</strong></td>
<td>62,472</td>
<td>4,403</td>
<td>17,368</td>
<td>2,218</td>
<td>3,733</td>
<td>90,194</td>
<td>$ 1,083</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>148,104</td>
<td>7,661</td>
<td>25,665</td>
<td>4,370</td>
<td>3,996</td>
<td>189,943</td>
<td>$ 2,239</td>
</tr>
</tbody>
</table>

Sources: LEK Consulting, GLOBOCAN, Company estimates.
1) Assume 2.5 treatments per patient.
2) Estimated ASP of ~$5K.

APAC Target Markets Represent Over $2 Billion Potential Market Opportunity
Appendix II
CHEMOSAT Melphalan for Metastatic Melanoma Phase 3 Pivotal Trial Details
Phase III Clinical Trial Design

**Randomized to CS**
92 patients: ocular or cutaneous melanoma

**CS/Melphalan**
Treat every 4 weeks x 4 rounds (responders can receive up to 6 rounds)

**Best Alternative Care (BAC)**
Investigator and patient decision (any and all treatments)

---

**Primary Trial Endpoint**
- Statistically significant difference in Hepatic Progression Free Survival (“hPFS”): \( p < 0.05 \)
- Over 80% of Oncologic drugs approved by FDA between 2005 – 2007 on endpoints other than overall survival

**Secondary Trial Endpoints**
- Hepatic response and duration of hepatic response
- Overall response and duration of overall response
- Overall Survival – Diluted by Cross Over
- SAP calls for analysis of various patient cohorts

**Hepatic Response – Metastatic Melanoma**

Modeled hPFS for Trial Success:
- 7.73 months (CS)
- vs.
- 4 months (BAC)

---

Pre-CS (Baseline)  Post-CS (22+ Months)

**Fully Powered, 93 Patient, Randomized, Multi-Center NCI Led Study**

CS = ChemoSaturation (CHEMOSAT)
Phase 3 Hepatic Progression-free Survival (ITT)

Survival probability

Hazard Ratio: 0.35
(CI: 0.23-0.54)

CS-PHP Demonstrated a 5x Improvement in Primary Endpoint of hPFS
Phase 3 Overall Progression-free Survival (ITT)

- **Hazard Ratio:** 0.36 (CI: 0.23-0.57)
- **Survival probability**
  - 0.0, 0.2, 0.4, 0.6, 0.8, 1.0
  - Months: 0, 30, 5, 35, 10, 15, 20, 25

**CS also Demonstrated a Highly Statistically Significant Improvement in Overall PFS**
Phase 3 Overall Survival (ITT)

Survival probability

Hazard Ratio: 1.08  
(CI: 0.69-1.68)

55% crossover

Overall Survival Confounded by Crossover Study Design
Appendix III
Published Phase I/II Studies of Doxorubicin with PHP (percutaneous hepatic perfusion) for HCC
## Phase I/II Studies of PHP-Doxorubicin For HCC

<table>
<thead>
<tr>
<th>No. of pts</th>
<th>No. of PHP/pt</th>
<th>Disease stage (tumor diameter)</th>
<th>Treatment</th>
<th>Median survival (mo)</th>
<th>Response Rates</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCC (n=79)</td>
<td>1–4</td>
<td>IV A: n=66 IV B: n=13</td>
<td>Doxorubicin 60–150 mg/m² Cisplatin 50–150 mg/m² Mitomycin C 50–200 mg/m²</td>
<td>16</td>
<td>HCC pts RR 64.5% 5-year survival 20.3%</td>
<td>Kobe ¹ Phase I/II</td>
</tr>
<tr>
<td>CHM (n=23)</td>
<td>1–2</td>
<td>All multiple bilobar Extrahepatic disease in 52%</td>
<td></td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCC (n=11)</td>
<td>1–3</td>
<td>Mean 9.5 cm</td>
<td>Doxorubicin 60–120 mg/m²</td>
<td>6.5</td>
<td>RR 20%</td>
<td>MDACC² Phase I</td>
</tr>
<tr>
<td>HCC (n=5)</td>
<td></td>
<td></td>
<td></td>
<td>13 (responders) 2 (non-responders)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHM (n=8)</td>
<td>2–4</td>
<td>Extrahepatic disease in 17%</td>
<td>Doxorubicin 50–120 mg/m² 5-FU 1000–5000 mg/m²</td>
<td>NR</td>
<td>RR 22%</td>
<td>Yale³ Phase I</td>
</tr>
<tr>
<td>Other (n=8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCC (n=7)</td>
<td>1–10</td>
<td>NR</td>
<td>Doxorubicin 90–120 mg/m²</td>
<td>23 (responders) 8 (non-responders)</td>
<td>RR 58%</td>
<td>Yale⁴ Phase I</td>
</tr>
<tr>
<td>Other (n=11)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Delivered Safely in Multiple Studies with Promising Response Rates
Concentrating the Power of Chemotherapy™